


Amendments to the Claims:

1. (Currently amended) A method for treating pain in a patient in need thereof comprising administering to the patient an ~~effective~~ amount of substantially enantiomerically pure (S)-norketamine ~~a compound of formula 2~~



wherein:

~~R₁=H, R₂=H.~~

~~and~~ or a pharmaceutically acceptable salt or solvate ~~salts or solvates~~ thereof,
which falls in the range of about 0.01 to about 20 mg/kg of body weight of the patient
and which, as determined by a physician or medical care provider, is effective to treat pain
while not inducing dysphoria.

2. (Currently amended) The method ~~according to Claim 1, of claim 1~~ in which ~~wherein said compound~~ substantially enantiomerically pure (S)-norketamine is administered to the patient. ~~, or any pharmaceutically acceptable salts thereof.~~

3.-4. (Canceled)

5. (Currently amended) The method of claim 1 in which the amount administered falls in a range of according to Claim 1, ~~wherein said effective amount of said compound is~~ about 1% to about 50% of an amount used to induced anesthesia.

6. (Currently amended) The method of claim 1 in which the amount administered falls in a range of ~~according to Claim 1, wherein said effective amount of said compound is~~ about 5% to about 40% of an amount used to induced anesthesia.

7. (Currently amended) The method of claim 1 in which the amount administered falls in a range of ~~according to Claim 1, wherein said effective amount of said compound is~~ about 10% to about 20% of an amount used to induced anesthesia.

8. (Canceled)

9. (Currently amended) The method of claim 1 in which the amount administered falls in a range of ~~according to Claim 1, wherein said effective amount of said compound is~~ about 0.05 to about 8 mg/kg of body weight of the patient.

10. (Currently amended) The method of claim 1 in which a pharmaceutically acceptable salt of substantially enantiomerically pure (S)-noreketamine is administered to the patient. ~~wherein said pain is breakthrough pain or pain associated with wind up.~~

11.-12. (Canceled)

13. (Currently amended) The method of claim 1 in which the amount ~~according to Claim 1, wherein said effective amount of said compound~~ is administered over a 24 hour period.

14. (Currently amended) The method of claim 1 in which the amount ~~according to Claim 1, wherein said effective amount of said compound~~ is administered in conjunction with a narcotic analgesic effective to alleviate pain.

15. (Currently amended) The method of claim 1, ~~according to Claim 14,~~ further comprising decreasing a dose of the narcotic analgesic.

16. (Currently amended) A method for self-treating pain in a subject comprising self-administering on an outpatient basis via one or more of routes selected from the a transmucosal, transdermal, nasal, oral, or pulmonary route, ~~routes,~~ or any combination of the foregoing an amount of substantially enantiomerically pure (S)-norketamine, or a

pharmaceutically acceptable salt or solvate thereof, which falls in the range of about 0.01 to about 20 mg/kg of body weight of the patient and which, as determined by a physician or medical care provider, is effective to treat pain while not inducing dysphoria. ~~thereof, about 0.01 to about 20 mg/kg of body weight of a compound of Claim 1 which is effective to alleviate pain.~~

17. (Currently amended) The method of ~~claim~~ Claim 16 wherein in which the route of administration is oral. ~~an effective amount of said compound is determined by a physician or medical care provider to be below a level that induces dysphoria.~~

18.-27. (Canceled)

28. (Currently amended) The method of claim 16 in which according to Claim 16 wherein said pain is selected from the group consisting of breakthrough pain, pain associated with wind-up, chronic pain and ~~or~~ neuropathic pain.

29.-70. (Canceled)

71. (Currently amended) The method of ~~Claim 1,~~ claim 1 in which the amount wherein said compound is administered to the patient said subject via a route selected from the group consisting of intravenous, intramuscular, subcutaneous, intrathecal, and epidural.

72. (Canceled)

73. (New) A method for treating breakthrough pain in a patient in need thereof comprising administering to the patient an amount of substantially enantiomerically pure (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat breakthrough pain while not inducing dysphoria.

74. (New) The method of claim 73 which further comprises administering a narcotic analgesic.

75. (New) The method of claim 73 in which the amount is administered orally.
76. (New) The method of claim 73 in which the amount administered falls in the range of about 0.01 to about 20 mg/kg of body weight of the patient.
77. (New) The method of claim 73 in which the amount is administered falls in the range of about 0.05 to about 8 mg/kg of body weight of the patient.
78. (New) A method for treating pain associated with wind-up in a patient in need thereof comprising administering to the patient an amount of substantially enantiomerically pure (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat pain associated with wind-up while not inducing dysphoria.
79. (New) A method for treating chronic pain in a patient in need thereof comprising administering to the patient an amount of substantially enantiomerically pure (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat chronic pain up while not inducing dysphoria.
80. (New) A method for treating neuropathic pain in a patient in need thereof comprising administering to the patient an amount of substantially enantiomerically pure (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof, which, as determined by a physician or medical care provider, is effective to treat neuropathic pain up while not inducing dysphoria.
81. (New) An oral dosage form comprising substantially enantiomerically pure (S)-norketamine or a pharmaceutically acceptable salt or solvate thereof and one or more pharmaceutically acceptable excipients, which dosage form, when self-administered in an amount falling in the range of about 0.01 mg/kg to about 20 mg/kg of body weight of the patient, is effective, as determined by a physician or medical care provider, to treat pain while not inducing dysphoria.

82. (New) The oral dosage form of claim 81 which comprises substantially enantiomerically pure (S)-norketamine.

83. (New) The oral dosage form of claim 81 which comprises a pharmaceutically acceptable salt of substantially enantiomerically pure (S)-norketamine.